BIP
WST icon

Blueprint Investment Partners’s West Pharmaceutical WST Stock Holding History

Blueprint Investment Partners’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,219
Closed -$457K – 153
2023
Q3 		$457K Sell
1,219
-89
-7% -$34.4K 0.15% 71
2023
Q2 		$500K Buy
1,308
+83
+7% +$29.7K 0.18% 83
2023
Q1 		$424K Buy
+1,225
New +$358K 0.1% 152
2022
Q2 		– Sell
-1,111
Closed -$456K – 228
2022
Q1 		$456K Buy
1,111
+89
+9% +$34.8K 0.12% 101
2021
Q4 		$479K Buy
1,022
+245
+32% +$105K 0.12% 130
2021
Q3 		$330K Buy
+777
New +$328K 0.16% 89

Other funds holding WST

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
APG Asset Management
APG Asset Management Amsterdam, Netherlands $31.6B AUM 19.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Blueprint Investment Partners's WST Position: Q4 2023 in Review

Blueprint Investment Partners sold out of West Pharmaceutical (WST) in Q4 2023, closing a stake of 1,219 shares — an estimated $457K sold.

Blueprint Investment Partners first reported a position in WST in Q3 2021 and held it in 6 quarters. The position peaked at $500K in Q2 2023. 782 funds tracked by Wall St. Rank hold WST as of Q4 2023.

  • Blueprint Investment Partners reported no remaining West Pharmaceutical position as of Q4 2023 after selling out during the quarter.
  • Blueprint Investment Partners sold 1,219 West Pharmaceutical shares in Q4 2023, an estimated $457K.
  • Blueprint Investment Partners first reported a position in West Pharmaceutical in Q3 2021 and held it in 6 quarters.
  • Blueprint Investment Partners's West Pharmaceutical position peaked at $500K in Q2 2023.
  • 782 funds tracked by Wall St. Rank held West Pharmaceutical as of Q4 2023.

Based on Blueprint Investment Partners's 13F filing for Q4 2023, filed 13 Feb 2024.